Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Trial Profile

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-010
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 10 Sep 2019 Results of Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials, presented at the 20th World Conference on Lung Cancer.
    • 09 Sep 2019 According to an Merck & Co media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress.
    • 01 Jul 2019 Results assesasing pharmacological cost of first- and second-line treatments with pembrolizumab, nivolumab and atezolizumab using 6 phase III trials (KEYNOTE-024, -010, CheckMate-026, 017, 057 and OAK) published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top